Slingshot members are tracking this event:

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AZN Community voting in process
LLY Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 22, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fast Track Status, Azd3293, Bace Inhibitor, Oral Beta Secretase Cleaving Enzyme